Sandeep Khurana

Dr. Sandeep Khurana


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Antioxidants
Verified
Journal Article
Open access
PDF file
MTMenaka Thounaojam
Menaka Thounaojam
RJRavirajsinh Jadeja
Ravirajsinh Jadeja
MWMarie Warren
Marie Warren
FPFolami L. Powell
Folami L. Powell
RRRaghavan P Raju
Raghavan P Raju
Manuela BartoliManuela Bartoli
Manuela Bartoli
Stress-associated premature senescence (SAPS) is involved in retinal microvascular injury and diabetic retinopathy. We have investigated the role and mode of action of miR-34a in retinal endothelial cells senescence in response to glucidic stress. Human retinal microvascular endothelial cells (HuREC) were exposed to glucidic stress (high glucose (HG) = 25 mM d-glucose) and compared to cells exposed to normal glucose (NG = 5 mM) or the osmotic control l-glucose (LG = 25 mM). HG stimulation of HuREC increased the expression of miR-34a and induced cellular senescence. HG also increased the expression of p16ink4a and p21waf1, while decreasing the histone deacetylase SIRT1. These effects were associated with diminished mitochondrial function and loss of mitochondrial biogenesis factors (i.e., PGC-1α, NRF1, and TFAM). Transfection of the cells with miR-34a inhibitor (IB) halted HG-induced mitochondrial dysfunction and up-regulation of senescence-associated markers, whereas miR-34a mimic promoted cellular senescence and mitochondrial dysfunction. Moreover, HG lowered levels of the mitochondrial antioxidants TrxR2 and SOD2, an effect blunted by miR-34a IB, and promoted by miR-34a mimic. 3’-UTR (3’-untranslated region) reporter assay of both genes validated TrxR2 as a direct target of miR-34a, but not SOD2. Our results show that miR-34a is a key player of HG-induced SAPS in retinal endothelial cells via multiple pathways involved in mitochondrial function and biogenesis.

16 April 2019 in Hepatology International
Verified
Journal Article
Closed access
PDF file
SKSandeep Khurana
Sandeep Khurana
WBWaseem Butt
Waseem Butt
HKHarshit S. Khara
Harshit S. Khara
AJAmitpal S. Johal
Amitpal S. Johal
SWSara F. West
Sara F. West
DDDavid L. Diehl
David L. Diehl

26 January 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
UIUmair Iqbal
Umair Iqbal
RJRavirajsinh Jadeja
Ravirajsinh Jadeja
Harshit KHaraHarshit KHara
Harshit KHara
SKSandeep Khurana
Sandeep Khurana
Hepatic encephalopathy (HE) is a common neurological consequence in patients with cirrhosis and has a healthcare burden of USD 5370 to 50,120 per patient annually. HE significantly hampers the quality of life and is a major cause of morbidity and mortality. Patients with cirrhosis are at a high risk for protein-calorie malnutrition due to altered metabolism. Current evidence has changed the old belief of protein restriction in patients with cirrhosis and now 1.2 to 1.5 g/kg/day protein intake is recommended. Case series and studies with small numbers of participants showed that a vegetarian protein diet decreases the symptoms of HE when compared to a meat-based diet, but the evidence is limited and requires further larger randomized controlled trials. However, vegetable or milk-based protein diets are good substitutes for patients averse to meat intake. Branch chain amino acids (BCAA) (leucine, isoleucine and valine) have also been shown to be effective in alleviating symptoms of HE and are recommended as an alternative therapy in patients with cirrhosis for the treatment of HE. In this review, we provide an overview of current literature evaluating the role of protein intake in the management of HE in cirrhosis.

1 November 2019 in Biochemical Pharmacology
Verified
Journal Article
Closed access
RJRavirajsinh Jadeja
Ravirajsinh Jadeja
XCXin Chu
Xin Chu
CWCraig Wood
Craig Wood
MBManuela Bartoli
Manuela Bartoli
SKSandeep Khurana
Sandeep Khurana

18 May 2018 in Current Drug Targets
Verified
Journal Article
Closed access
RJRavirajsinh Jadeja
Ravirajsinh Jadeja
VRVikrant P. Rachakonda
Vikrant P. Rachakonda
SKSandeep Khurana
Sandeep Khurana
Over the past few decades, evidence accumulated to indicate that parasympathetic innervation regulates liver injury and regeneration. Liver derives its parasympathetic input via vagus nerve. In animal models, vagus nerve stimulation and transection are frequently used to determine the impact of parasympathetic input on liver injury responses. Such strategies provide limited understanding of post-neuronal mechanisms involved in regulation of liver injury. The hepatic branch of vagus nerve releases acetylcholine (ACh), which activates muscarinic and nicotinic receptors in hepatocytes as well as non-parenchymal cells to modulate cellular functions. Moreover, vagus nerve releases other neurotransmitters such as vasoactive intestinal peptide (VIP), which also modulates liver injury responses and hemodynamics. Therefore, our understanding of the post-neuronal modulation of liver injury in models utilizing vagus nerve activity remains limited. Gene-silencing technologies and pharmacological manipulation of receptor activity have not only improved our understanding of the role of specific cholinergic receptors but also elucidated the role of various liver cell sub-populations in modulating liver injury response. With advent of organ- and cell-specific transgenic mice, our understanding of neural regulation of liver injury is likely to improve further. This review comprehensively provides of our current understanding of cholinergic regulation of liver injury, and points to potential therapeutic targets to treat liver injury.

1 June 2018 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
RJRavirajsinh Jadeja
Ravirajsinh Jadeja
MTMenaka C. Thounaojam
Menaka C. Thounaojam
MBManuela Bartoli
Manuela Bartoli
SKSandeep Khurana
Sandeep Khurana